Clinical Trials Logo

Vasculopathy clinical trials

View clinical trials related to Vasculopathy.

Filter by:
  • None
  • Page 1

NCT ID: NCT06392347 Recruiting - Vasculopathy Clinical Trials

Evaluation of Accelerated Sampling Techniques for Vessel Wall Imaging

Start date: October 23, 2023
Phase:
Study type: Observational

The purpose of this study is to compare and evaluate a faster MR image that has been optimized to look at participants blood vessel walls.

NCT ID: NCT05485467 Completed - Clinical trials for Heart Transplant Failure

The Role of CD34 + Stem Cells and Biomarkers in the Development of CAV in HTX Patients

Start date: June 1, 2022
Phase:
Study type: Observational

Coronary allograft vasculopathy represents one of the major limiting factors of long-term survival in heart transplant recipients. While extensively researched, the underlying mechanisms of coronary allograft vasculopathy (CAV) after heart transplantation remain incompletely understood. As CD34+ cells represent one of the key determinants of coronary vascular homeostasis we investigated the potential association between CAV and CD34+ cell count in heart transplant recipients.

NCT ID: NCT05251129 Not yet recruiting - Vasculopathy Clinical Trials

Statin InTensity to Prevent Coronary Artery Vasculopathy After Heart Transplantation

SToP-CAV
Start date: January 2025
Phase: N/A
Study type: Interventional

The investigator's propose to conduct an open-label randomized controlled trial to determine if higher intensity statin (HS) can reduce CAV in comparison to lower intensity statin (LS) after HT. All consecutive patients that meet eligibility criteria will be approached for participation. After heart transplantation, participants (n=70) will be randomized in a 1:1 manner to either HS (Atorvastatin 80 mg daily) or LS (Pravastatin 40 mg daily). Study participation will be for 2 years from the time of randomization.

NCT ID: NCT04051086 Not yet recruiting - Vasculopathy Clinical Trials

Quantification of Elastin Markers Synthesis in Williams-Beuren Syndrome and 7q11.23 Micro-duplication Syndrome

ELAST7
Start date: October 2019
Phase: N/A
Study type: Interventional

Introduction: Williams-Beuren syndrome is a rare genetic disorder caused by a 7q11.23 microdeletion. The phenotype associates vasculopathy (arterial stenosis, hypertension), dimorphism and intellectual disability. Microdeletion includes several genes: ELN encodes for elastin and the haplo-insufficiency (only 1 functional copy) causes vasculopathy. The primary objective is to quantify plasma and urinary levels of elastin peptides in Williams-Beuren patients and 7q11.23 micro-duplication syndrome patients in order to correlate the levels of these markers with the number of copies of ELN gene (proportional positive relationship "gene copy number - circulating levels of markers) Materials and Methods: This prospective study will be carried out in Lyon at the "Hôpital Femme-Mère-Enfant" for 2 years. 3 groups of patients will be studied: Williams-Beuren patients (N=20), micro-duplication 7q11.23 syndrome patients (N=10) and healthy patients (N=60). Subjects will be followed for 1 day. Clinical examination (weight, height, blood pressure) and biological sample collection (blood and urine sample) will be carry out for Williams Beuren and micro-duplication 7q11.23 patients group. A large majority of visits will be part of patients' usual care. A large part of patients are systematically seen in consultation once a year. For healthy group, only biological sample collection will be carry out. The PE concentrations will be assessed and compared between the three groups of patients.

NCT ID: NCT03537742 Enrolling by invitation - Vasculopathy Clinical Trials

PCSK9 Inhibition After Heart Transplantation

Start date: May 13, 2019
Phase: Phase 2
Study type: Interventional

The focus of this study is to test the safety and efficacy of the PCSK9 inhibitor, alirocumab when administered early after heart transplantation (HT).The main objective of this project is to test the safety and impact on cardiac allograft vasculopathy (CAV) of alirocumab when given early after HT.

NCT ID: NCT00384540 Completed - Allograft Clinical Trials

Cardiac Allograft Vasculopathy and Dobutamine Stress Echocardiography / Brain Natriuretic Peptide Coupling

Start date: September 2006
Phase: N/A
Study type: Interventional

Primary purpose :To early detect cardiac allograft vasculopathy and to identify patients with high risk of cardiac events, by coupling the analysis of the kinetics of the brain natriuretic peptide ( BNP) with that of the left ventricle (LV) during a dobutamine stress echocardiography. Hypothesis : Plasma BNP elevation and abnormalities of LV kinetic during the ESD, will be associated with the presence of allograft vasculopathy and the arisen of cardiovascular events.